Small interfering RNA (siRNA) is a class of nucleic acid-based drugs (NABDs) able to block gene expression by interaction with mRNA before its translation. Small interfering RNAs (siRNAs) therefore present extraordinary potential due to their ability to silence the expression of disease-causing genes. Even if the mechanism of action has been successfully investigated (Nobel Prize in Physiology or Medicine 2006 to Andrew Z. Fire and Craig C. Mello “for their discovery of RNA interference – gene silencing by double-stranded RNA”) and siRNA drugs can be candidates to fight, in principle, any diseases. However, the practice of siRNA-based therapies is restricted because of relevant inconveniences. SiRNAs are negatively charged large macromolecules and this entails difficult crossing of cell membranes; they undergo rapid degradation by plasma enzymes and are easily subjected to fast hepatic/renal clearance sequestration. These features seriously hinder siRNAs’ usability in therapeutics. Currently, the scientific community focused on gene therapy research is developing studies to overcome the obstacles related to siRNA’s features.

This Special Issue of *Pharmaceutics* titled “Drug Delivery of siRNA Therapeutics” aims to present the state of the art of siRNA delivery, embracing investigation strategies of international research groups with different experiences and skills. The Special Issue will thus be devoted to presenting the current connections between experimental and in silico approaches for therapies based on siRNA delivery, accounting for all the most promising techniques based on liposomes, polymeric and inorganic nanoparticles, aptamers, chemical modification of siRNAs, and so on.

Reviews (five) and research papers (eight) constitute this Special Issue. A representative international scientific community focused on gene-therapies researches is represented by 12 different countries involving 75 scientists with multidisciplinary skills.

In the reviews, different research activities cover several disciplines of investigation mainly focused on approaches of siRNA therapies to combat several kinds of cancer in laboratory conditions and the current state of siRNA–lipid delivery systems in clinical trials.

In Marson et al., [1] studies on poly(amidoamine)-based dendrimers as attractive nanovectors for siRNA delivery into cells, were presented. In particular, an introduction to RNAi-based therapeutics and the advantages offered by dendrimers as siRNA nanocarriers were discussed. Subsequent linked studies reported in Laurini et al., [2] present the development of poly(amidoamine)-based amphiphilic dendrons—structures able to auto-organize themselves into nanosized micelles which ultimately outperform their covalent dendrimer counterparts in in vitro and in vivo gene silencing. In Barba et al., [3] the current status of siRNA-lipid delivery systems in clinical trials was addressed, offering an updated overview on the clinical goals and the next challenges of this new class of therapeutics which will soon replace traditional drugs. Farra et al., [4] focused their studies on the description of the therapeutic potential of siRNAs and polymer–lipid-based delivery systems for ovarian cancer. After a brief description of ovarian cancer and siRNA features, they summarized the
strategies employed to minimize siRNA delivery problems, the targeting strategies to ovarian cancer and the preclinical models available. They also discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. In Dinis Ano Bom et al., [5] attention was devoted to the use of aptamers as delivery agents of siRNA in nanoparticle formulations in cancer treatments, alone or in combination with chemotherapy.

Research papers deal with experimental new strategies to design and develop innovative suitable and effective vectors for siRNA delivery such as liposomes, dendrimers, aptamers, polymer-lipid systems, polymeric, co-polymeric and magnetic nanoparticles.

Stiina Kontturi et al., [6] aimed their studies at the development of efficient and safe administration systems devoted to the delivery of oligonucleotide-based drugs. In particular, they produced a light-triggered liposomal delivery system for oligonucleotide delivery based on a non-cationic and thermosensitive liposome with indocyanine green as a photosensitizer ingredient. Hao et al., [7] focused their studies on the combination of chemotherapeutic drugs and siRNA as an emerging modality for cancer therapy. They developed a functionalized mixed micelle-based delivery system for targeted co-delivery of methotrexate and survivin siRNA. Hattori et al., [8] presented studies on three types of cationic liposomes/siRNA complexes (siRNA lipoplexes) on gene-silencing actions in tumor cells. They used three types of cationic cholesterol derivatives to investigate an optimal formulation to achieve the best performance in terms of gene-silencing and cellular uptake effects. In Egorova et al., [9] researches on modular peptide carriers for the delivery of siRNAs to therapeutic angiogenesis inhibition were performed. In particular, the transfection properties of siRNA as polyplexes were studied in breast cancer cells and endothelial cells. Fatemian et al., [10] investigated the use of inorganic pH-dependent carbonate apatite nanoparticles to efficiently deliver various classes of therapeutics into cancer cells. Co-delivery of drugs and genetic materials (siRNAs) was studied in in vivo research. Ewe et al., [11] presented a research on the chemical modifications of polyethylenimines used to produce polymeric nanoparticles, promising structures towards the development of more efficient non-viral delivery systems. In particular, they concentrated their attention on tyrosine-modified polyethyleneimines with low or very low molecular weight for siRNA delivery. Jin et al., [12] focused their work on polyethyleneimine-modified magnetic Fe$_3$O$_4$ nanoparticles prepared for the delivery of therapeutic siRNAs to contrast oral cancer cells’ growth. Craparo et al., [13] studied the formulation and properties of a novel protonable copolymer, based on polyaspartamide, able to form polyplex structures with siRNA to be used in antiasthmatic therapy.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Marson, D.; Laurini, E.; Aulic, S.; Fermeglia, M.; Pricl, S. Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled in Silico-Experimental Studies. Part I: Covalent siRNA Nanocarriers. Pharmaceutics 2019, 11, 351. [CrossRef] [PubMed]
2. Laurini, E.; Marson, D.; Aulic, S.; Fermeglia, M.; Pricl, S. Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled in Silico-Experimental Studies. Part II: Self-Assembled siRNA Nanocarriers. Pharmaceutics 2019, 11, 324. [CrossRef] [PubMed]
3. Barba, A.A.; Bochicchio, S.; Dalmore, A.; Lamberti, G. Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications. Pharmaceutics 2019, 11, 360. [CrossRef] [PubMed]
4. Farra, R.; Maruna, M.; Perrone, F.; Grassi, M.; Benedetti, F.; Maddaloni, M.; Boustani, M.E.; Parisi, S.; Rizzolli, E.; Forte, G.; et al. Strategies for Delivery of siRNAs to Ovarian Cancer Cells. Pharmaceutics 2019, 11, 547. [CrossRef] [PubMed]
5. Dinis Ano Bom, A.P.; da Costa Neves, P.C.; de Almeida, C.E.B.; Silva, D.; Missalidis, S. Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer. Pharmaceutics 2019, 11, 684. [CrossRef] [PubMed]
6. Kontturi, L.-S.; van den Dikkenberg, J.; Urtti, A.; Hennink, W.; Mastrobattista, E. Light-Triggered Cellular Delivery of Oligonucleotides. Pharmaceutics 2019, 11, 90. [CrossRef] [PubMed]
7. Hao, F.; Lee, R.; Yang, C.; Zhong, L.; Sun, Y.; Dong, S.; Cheng, Z.; Teng, L.; Meng, Q.; Lu, J.; et al. Targeted Co-Delivery of siRNA and Methotrexate for Tumor Therapy via Mixed Micelles. *Pharmaceutics* 2019, 11, 92. [CrossRef] [PubMed]

8. Hattori, Y.; Shimizu, S.; Ozaki, K.; Onishi, H. Effect of Cationic Lipid Type in Folate-PEG-Modified Cationic Liposomes on Folate Receptor-Mediated siRNA Transfection in Tumor Cells. *Pharmaceutics* 2019, 11, 181. [CrossRef] [PubMed]

9. Egorova, A.A.; Shtykalova, S.V.; Maretina, M.A.; Sokolov, D.I.; Selkov, S.A.; Baranov, V.S.; Kiselev, A.V. Synergistic Anti-Angiogenic Effects Using Peptide-Based Combinatorial Delivery of siRNAs Targeting VEGFA, VEGFR1, and Endoglin Genes. *Pharmaceutics* 2019, 11, 261. [CrossRef] [PubMed]

10. Fatemian, T.; Moghimi, H.R.; Chowdhury, E.H. Intracellular Delivery of siRNAs Targeting AKT and ERBB2 Genes Enhances Chemosensitization of Breast Cancer Cells in a Culture and Animal Model. *Pharmaceutics* 2019, 11, 458. [CrossRef] [PubMed]

11. Ewe, A.; Noske, S.; Karimov, M.; Aigner, A. Polymeric Nanoparticles Based on Tyrosine-Modified, Low Molecular Weight Polyethylenimines for siRNA Delivery. *Pharmaceutics* 2019, 11, 600. [CrossRef] [PubMed]

12. Jin, L.; Wang, Q.; Chen, J.; Wang, Z.; Xin, H.; Zhang, D. Efficient Delivery of Therapeutic siRNA by Fe3O4 Magnetic Nanoparticles into Oral Cancer Cells. *Pharmaceutics* 2019, 11, 615. [CrossRef] [PubMed]

13. Craparo, E.F.; Drago, S.E.; Mauro, N.; Giammona, G.; Cavallaro, G. Design of New Polyaspartamide Copolymers for siRNA Delivery in Antiasthmatic Therapy. *Pharmaceutics* 2020, 12, 89. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).